Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer

Clinical Chemistry

Volumn 55, Issue 7, 2009, Pages 1307-1315

  Xiao, Yan ^a   Gao, Xiugong ^b   Maragh, Samantha ^a   Telford, William G ^c   Tona, Alessandro ^a,d  

^a NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

^b Translabion   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; QUANTUM DOT;

ACCURACY; ANALYTIC METHOD; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL LEVEL; CELL STRAIN MCF 7; CELL STRAIN SK BR 3; CLINICAL DECISION MAKING; CONSENSUS; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENOTYPE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LASER SCANNING CYTOMETRY; PROGNOSIS; PROTEIN EXPRESSION; QUALITY CONTROL; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BREAST NEOPLASMS; CELL LINE, TUMOR; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; QUALITY CONTROL;

BACTERIA (MICROORGANISMS);

EID: 67650085343     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.120576     Document Type: Article

References (23)

1. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-6.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
3. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
4. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-904.
5. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334-56.
6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
7. Hayes DF, Picard MH. Heart of darkness: the downside of trastuzumab. J Clin Oncol 2006;24:4056-8.
8. Jimenez RE, Wallis T, Tabasczka P, Visscher DW. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol 2000;13:37-45.
9. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-4.
10. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032-8.
11. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-7.
12. Hammond ME, Barker P, Taube S, Gutman S. Standard reference material for Her2 testing: report of a National Institute of Standards and Technology-sponsored Consensus Workshop. Appl Immunohistochem Mol Morphol 2003;11:103-6.
13. Xiao Y, Gao X, Gannot G, Emmert-Buck MR, Srivastava S, Wagner PD, et al. Quantitation of HER2 and telomerase biomarkers in solid tumors with IgY antibodies and nanocrystal detection. Int J Cancer 2008;122:2178-86.
14. Xiao Y, Barker PE. Semiconductor nanocrystal probes for human metaphase chromosomes. Nucleic Acids Res 2004;32:e28.
15. Bankfalvi A, Boecker W, Reiner A. Comparison of automated and manual determination of HER2 status in breast cancer for diagnostic use: a comparative methodological study using the Ventana BenchMark automated staining system and manual tests. Int J Oncol 2004;25:929-35.
16. Xiao Y, Telford WG, Ball JC, Locascio LE, Barker PE. Semiconductor nanocrystal conjugates, FISH and pH. Nat Methods 2005;2:723.
17. Morgan JM. A protocol for preparing cell suspensions with formalin fixation and paraffin embedding which minimizes the formation of cell aggregates. J Cell Pathol 2001;5:171-80.
18. Elledge RM, Osborne CK. Oestrogen receptors and breast cancer. BMJ 1997;314:1843-4.
19. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.
20. Sompuram SR, Kodela V, Zhang K, Ramanathan H, Radcliffe G, Falb P, et al. A novel quality control slide for quantitative immunohistochemistry testing. J Histochem Cytochem 2002;50:1425-34.
21. Allred DC. Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer? Am J Clin Pathol 1993;99:1-3.
22. Riera J, Simpson JF, Tamayo R, Battifora H. Use of cultured cells as a control for quantitative immunocytochemical analysis of estrogen receptor in breast cancer. The Quicgel method. Am J Clin Pathol 1999;111:329-35.
23. Rhodes A, Jasani B, Couturier J, McKinley MJ, Morgan JM, Dodson AR, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002;117:81-9.